Compare First Trust Cloud Computing ETF (SKYY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust Cloud Computing ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? First Trust Cloud Computing ETF trades at $161.15, while Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B). Which is the better fit depends on your goals.
| SKYY | VRTX | |
|---|---|---|
52-Week High | $161.09 | $529.65 |
52-Week Low | $104.16 | $376.62 |
Market Cap | — | $132.79B |
Sector | — | Health |
Enterprise Value | — | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SKYY, trading at $156.17, gained 3.71% today, reflecting strong bullish momentum from moving averages and positive sentiment around cloud computing and AI trends. The ETF's technical indicators show overbought conditions with RSI levels above 76, while support is firm near $155. Recent news highlights SKYY's diversified exposure to cloud infrastructure and AI, benefiting from secular growth in digital transformation.
Outlook remains positive due to AI adoption and cloud migration tailwinds, but risks include overvaluation concerns and competitive pressures. Investors should weigh the strong technical trend against high RSI readings and monitor earnings growth for sustained upside.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
